Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

A biomedical platform for targeted treatment of chronic inflammatory disease

Reference number
Coordinator BTB Pharma AB
Funding from Vinnova SEK 200 000
Project duration March 2017 - August 2017
Status Completed
Venture Innovative Startups

Purpose and goal

The purpose and main objective of this project were to develop a drug that can alleviate and/or cure autoimmune diseases, such as multiple sclerosis (MS). Previously we have used a drug and shown that it is possible, using an animal model for MS. However, this drug cannot be used in humans. A number of drugs, which can be used in the clinic, have been identified and investigated. Although we have not yet found a drug that is efficient, we now understand how to produce a drug that functions effectively.

Expected results and effects

This project had three work packages; two of experimental character and one to develop a business and strategy plan. We have tested a number of substances for their inhibiting effects on the disease MS, using an animal model. In previous experiments, substances were identified that works well in the animal model. However, these cannot be used on humans. A number of candidates, which are for human use, have been tested. Unfortunately, we have not identified one that shows protection. The business and strategy plan has been written. Our method and the market for our drug look promising.

Planned approach and implementation

The work packages have been implemented as expected, but with some difficulties. The experimental parts have required more time and resources than expected. Experiments of biological nature are often very sensitive to variations that are difficult to control (the surroundings). These have worked well. The MS animal model has been set up and positive and negative control substances work accordingly. The difficulties have been in producing the drugs that were to be tested in the MS animal model. Experts in this field have helped us and are now producing material we will test soon.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2017-00670

Page statistics